Value of two-cycle docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy in hypopharyngeal carcinoma.

Abstract

Various studies have investigated laryngeal function and survival after induction chemotherapy in hypopharyngeal carcinoma, but potential factors to help predict response rates after induction chemotherapy remain unknown. This retro- spective study evaluated which factors are related to an ineffective response to two-cycle docetaxel, cisplatin, and 5-fluoro- uracil (TPF) induction chemotherapy in hypopharyngeal carcinoma to determine potential candidates for this treatment in clinical practice. From Jan 2005 to Dec 2015, 81 patients diagnosed with hypopharyngeal squamous cell carcinoma based on a pathological examination were analyzed. They were administered two-cycle TPF induction chemotherapy, and magnetic resonance imaging was performed before and after induction chemotherapy. The mean survival time was 5.7 years (95% confidence interval, 5.1-6.2 years). The 1, 3, 5 and 6-year survival rates were 98.8%, 80.1%, 64.5%, and 54.2%, respectively. TPF induction chemotherapy was well tolerated; the main adverse effects resolved with symptomatic treatment. A response to TPF induction chemotherapy was associated with lymph node size, tumor grade, invasion region, T stage, and primary tumor. The following issues were significantly associated with an increasing non-response rate to two-cycle induction chemotherapy: increasing lymph node size, moderately differentiated squamous cell carcinoma, invasion of the esophagus along with the thyroid cartilage, and primary tumor in the piriform sinus. Lymph nodes of ≥2.15 cm, moderately differenti- ated tumor grade, or thyroid cartilage invasion were the best cutoff values for patients who did not respond to induction chemotherapy. However, the initial cancer site, cancer stage, and degree of cancer differentiation were not closely related to the efficacy of induction chemotherapy.

• Authors: X Luo, B Zhang, Z Lian, Y Dong, J Liu, S Pei, X Mo, L Zhang, W Huang, F Ouyang, B Guo, C Liang, S Zhang
• Journal: Neoplasma (Neoplasma) 2018 Vol. 65 Issue 2 Pg. 269-277 ISSN: 0028-2685 [Print] Slovakia
• PMID: 29368529 (Publication Type: Journal Article)

Chemical References

• Docetaxel
• Cisplatin
• Fluorouracil

Topics

• Antineoplastic Combined Chemotherapy Protocols
• Carcinoma, Squamous Cell (drug therapy)
• Cisplatin (therapeutic use)
• Docetaxel (therapeutic use)
• Fluorouracil (therapeutic use)
• Humans
• Induction Chemotherapy
• Survival Rate